5 questions answered from cited research · Plain language
New treatments for triple-negative breast cancer include chemo-immunotherapy (pembrolizumab plus platinum-based chemo) and potential NY-ESO-1 targeted therapies; for HER2-positive breast cancer, neoadjuvant targeted combinations and post-neoadjuvant trastuzumab emtansine are key
Read the full answer →Yes, the IMpassion130 trial showed atezolizumab plus nab-paclitaxel improved progression-free survival in PD-L1-positive metastatic triple-negative breast cancer, leading to FDA approval.
Read the full answer →Capecitabine is not a standard treatment for triple-negative breast cancer (TNBC); trastuzumab emtansine targets HER2-positive cancer, not TNBC. Neither is considered effective for TNBC.
Read the full answer →New immunotherapy options for triple-negative breast cancer include immune checkpoint inhibitors like pembrolizumab combined with chemotherapy, which improve survival in PD-L1-positive advanced disease and early-stage patients.
Read the full answer →Yes, adding immune checkpoint inhibitors (like pembrolizumab) to chemotherapy improves event-free survival and pathologic complete response in early-stage triple-negative breast cancer, with some trials also showing overall survival benefit.
Read the full answer →